Colorectal Cancer News
Genomic Health Announces Worldwide Availability of the Oncotype DX(R) Colon Cancer Test
Genomic Health, Inc. has announced worldwide commercial availability of its Oncotype DX(R) colon cancer test. This test is the first multigene expression test developed for the assessment of risk of recurrence in patients with stage II colon cancer. At the 2009 American Society of Clinical Oncology (ASCO) meeting, it was reported that the test is clinically validated to predict individual recurrence risk in stage II colon cancer patients following surgery.
"We believe the availability of the Oncotype DX colon cancer test will allow physicians, for the first time, to go beyond the limited set of clinical and pathologic markers they currently use in order to make a more precise risk assessment in the treatment planning for stage II colon cancer patients," stated Steven Shak, M.D., chief medical officer of Genomic Health.
Additionally, two new studies released at the ASCO Gastrointestinal Cancers Symposium provide further support for the use of the Oncotype DX colon cancer test as an independent predictor of recurrence risk in stage II colon cancer patients. The first study revealed that the Oncotype DX colon cancer Recurrence Score(R) result and number of nodes examined are independent predictors of recurrence in stage II colon cancer, and both should be considered when assessing individual recurrence risk. The second study analyzed various biological similarities and differences between stage II and III colon cancer. Results suggest the Oncotype DX Recurrence Score result is stage independent, and that it may also predict recurrence risk in stage III colon cancer.
The Oncotype DX colon cancer test is the first multigene expression test commercially available that has been clinically validated to predict risk of recurrence in patients with stage II colon cancer.
For more information about the the Oncotype DX(R) Colon Cancer Test, please visit the Genomic Health website.